Year: 2022

EDISON, N.J., Dec. 19, 2022 (GLOBE NEWSWIRE) — Zerify Inc., (OTCQB: ZRFY), the 21-year-old cybersecurity company focused on secure video conferencing solutions, today announced that 21st Century Marketing Group has licensed Zerify Defender to protect confidential client data. According to Anthony Lombardi, President of 21st Century Marketing Group, a NY based benefits brokerage and consulting firm, “purchasing Zerify Defender was important for myself and my agency for two reasons: 1) to protect the data and privacy of my clients both during video conferencing as well as the 24/7 protection of my laptop and desktop when enrolling employees and members into a number of online benefit portals, 2) with the workforce today that is remote or hybrid, offering a unique proactive benefit solution to my clients and their employees will be...

SOUTH SAN FRANCISCO, Calif., Dec. 19, 2022 (GLOBE NEWSWIRE) — Senti Biosciences, Inc. (Nasdaq: SNTI) (“Senti Bio”), a biotechnology company innovating next-generation cell and gene therapies using its proprietary gene circuit platform, today announced that Tim Lu, MD, PhD, Co-founder and Chief Executive Officer, will present a corporate overview at the 41st Annual J.P. Morgan Healthcare Conference on Wednesday, January 11, 2023 at 5:15 p.m. PT. A webcast of the presentation can be accessed under the “Events & Presentations” section of the Senti Bio website. About Senti BioOur mission is to create a new generation of smarter medicines that outmaneuver complex diseases using novel and unprecedented approaches. To accomplish this, we are building a synthetic biology platform that may enable us to program next-generation cell...

The phase 2b proof-of-concept trial will evaluate the novel compound, RL-007, for pro-cognitive effects in patients with Cognitive Impairment Associated with Schizophrenia (CIAS). The trial was initiated and has begun patient screening this month with first-patient-in anticipated by end-of-year. There are currently no FDA-approved medications for CIAS, a major cause of disability in 80% of patients with schizophrenia1. Topline results are expected in the first half of 2024.NEW YORK and BERLIN, Dec. 19, 2022 (GLOBE NEWSWIRE) — Today, atai Life Sciences N.V. (Nasdaq: ATAI) (“atai”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, announced the initiation of its Phase 2b proof-of-concept clinical trial for RL-007 for Cognitive Impairment Associated with Schizophrenia (CIAS),...

10th hospital in Germany to initiate a Senhance SystemThe Senhance Surgical System The Senhance Surgical System advances clinical intelligence by providing surgeons with augmented intelligence and digital tools to perform consistently superior surgery.RESEARCH TRIANGLE PARK, N.C., Dec. 19, 2022 (GLOBE NEWSWIRE) — Asensus Surgical, Inc. (NYSE American: ASXC), a medical device company that is digitizing the interface between the surgeon and the patient to pioneer a new era of Performance-Guided Surgery™, today announced that GPR Gesundheits- und Pflegezentrum Klinikum of Rüsselsheim (“GPR”), Germany has entered into an agreement to lease and utilize a Senhance® Surgical System. “With GPR’s broad laparoscopic use, the Senhance Surgical System is a perfect fit for high-volume surgical specialities like gynecology, urology...

— Additional indication is for the initial treatment of patients with metastatic, non-squamous, non-small cell lung cancer with no EGFR or ALK genomic tumor aberrations — — Represents the fifth indication for PEMFEXY, a ready-to-use liquid with a unique J-code approved to treat non-squamous non-small cell lung cancer and mesothelioma — WOODCLIFF LAKE, N.J., Dec. 19, 2022 (GLOBE NEWSWIRE) — Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (“Eagle” or the “Company”) announced today that the U.S. Food and Drug Administration (“FDA”) has approved an additional indication for PEMFEXY® (pemetrexed injection) in combination with pembrolizumab and platinum chemotherapy for the initial treatment of patients with metastatic, non-squamous, non-small cell lung cancer (“NSCLC”) with no EGFR or ALK genomic tumor aberrations....